PCP
HZNP

P2 Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

P2 Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-442,700
Closed -$8.77M – 15
2015
Q3 		$8.77M Buy
+442,700
New +$14M 1.7% 15

Other funds holding HZNP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

P2 Capital Partners's HZNP Position: Q4 2015 in Review

P2 Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2015, closing a stake of 442,700 shares — an estimated $8.77M sold.

P2 Capital Partners first reported a position in HZNP in Q3 2015 and held it in 1 quarter. The position peaked at $8.77M in Q3 2015. 202 funds tracked by Wall St. Rank hold HZNP as of Q4 2015.

  • P2 Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2015 after selling out during the quarter.
  • P2 Capital Partners sold 442,700 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2015, an estimated $8.77M.
  • P2 Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 1 quarter.
  • P2 Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $8.77M in Q3 2015.
  • 202 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2015.

Based on P2 Capital Partners's 13F filing for Q4 2015, filed 16 Feb 2016.